One doctor tried giving a blood-clotting medicine before and after the injection, and in one pair of twins, the one who took it earlier had less bruising — but this is just one case, so we don’t know if it really works.
Scientific Claim
Tranexamic acid (TXA), administered orally at 1300 mg twice daily for 8 days starting 12 hours before injection, is anecdotally associated with reduced bruising severity after CCH-aaes treatment, based on a single case report of identical twins.
Original Statement
“Early evidence suggests that oral TXA (1300 mg twice daily × 8 days) starting 12 hours before injection has been beneficial. In the case study shown in Figure 7, 32-year-old identical twins were treated... Twin B was given TXA 12 hours before injection... early bruising in twin A was more severe...”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim implies a causal link based on a single case report. The study design cannot support causation, and the verb 'has been beneficial' overstates the evidence.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1aThat oral TXA reduces bruising severity after CCH-aaes compared to placebo in a statistically significant and clinically meaningful way.
That oral TXA reduces bruising severity after CCH-aaes compared to placebo in a statistically significant and clinically meaningful way.
What This Would Prove
That oral TXA reduces bruising severity after CCH-aaes compared to placebo in a statistically significant and clinically meaningful way.
Ideal Study Design
A double-blind, placebo-controlled RCT of 120 adult women receiving CCH-aaes, randomized to oral TXA (1300 mg BID × 8 days, starting 12h pre-injection) vs. placebo, with primary outcome: bruising area (cm²) measured by digital imaging at 48h and 7d post-injection.
Limitation: Does not assess long-term pigmentation or safety in high-risk populations.
Prospective Cohort StudyLevel 2bThe real-world incidence of bruising reduction with TXA use across diverse clinical settings.
The real-world incidence of bruising reduction with TXA use across diverse clinical settings.
What This Would Prove
The real-world incidence of bruising reduction with TXA use across diverse clinical settings.
Ideal Study Design
A multicenter prospective cohort of 200 patients receiving CCH-aaes, with TXA use documented and bruising severity tracked via standardized photography and patient diaries over 3 treatment sessions.
Limitation: Cannot control for confounding variables like concomitant medications or injection technique.
Case-Control StudyLevel 3bWhether TXA use is associated with lower risk of prolonged hemosiderin staining.
Whether TXA use is associated with lower risk of prolonged hemosiderin staining.
What This Would Prove
Whether TXA use is associated with lower risk of prolonged hemosiderin staining.
Ideal Study Design
A case-control study comparing 50 patients with >6-month hemosiderin staining to 100 without, assessing prior TXA use, dose, timing, and skin type, adjusting for injection volume and number of sessions.
Limitation: Retrospective design limits causal inference.
Evidence from Studies
No evidence studies found yet.